20 Future Slovakian HealthTech and MedTech Leaders

Nelson Advisors
3 minutes ago
15 min read

The Vanguard of Central European Healthcare: An Analysis of 20 Future Slovakian HealthTech and MedTech Leaders

The Slovakian healthcare technology ecosystem has transitioned from a period of nascent development into a sophisticated phase of global integration and scientific leadership. This evolution is not a localised phenomenon but rather a strategic realignment of Central and Eastern Europe (CEE) as a hub for high-precision biotechnology and digital health.

At the heart of this transformation are 20 key individuals, founders, researchers and institutional leaders, whose work in artificial intelligence, molecular diagnostics and therapeutic platforms is redefining the boundaries of clinical medicine.

This report examines these leaders not merely as successful entrepreneurs but as the architects of a data-driven, patient-centric healthcare infrastructure that leverages Slovakia's deep academic heritage in biochemistry and engineering.

The Intersection of Clinical Cardiology and Computational Intelligence

Cardiovascular diseases remain the primary driver of global mortality, and the Slovakian ecosystem has emerged as a specialised center for solving the "time-to-intervention" problem through artificial intelligence. This specialisation is represented by a cluster of leaders who have successfully bridged the gap between the cardiology ward and the software laboratory.

1) Martin Herman and Robert Herman: The Architects of PMcardio

The most visible figures in the current Slovakian MedTech landscape are Martin Herman and Robert Herman, the co-founders of Powerful Medical. Their leadership has propelled the company from a domestic startup into a formidable international entity with operations in 16 European markets. Robert Herman, serving as the Chief Medical Officer, provides the clinical and scientific ballast for the organisation.

His role on the Research, Digital and Innovation Committee for the European Society of Cardiology underscores the high-level integration of the company into the continent’s medical policy-making bodies.

Their flagship product, PMcardio, represents a paradigm shift in emergency diagnostics. As a CE-certified Class IIb EU MDR medical device, it utilizes deep learning algorithms trained on millions of clinical outcomes to interpret electrocardiograms (ECGs) across 39 different indications.

The clinical impact of their leadership is quantifiable; the implementation of their care coordination platform has demonstrated a 13-hour reduction in door-to-balloon time for heart attack patients and a 67% decrease in false-positive catheterisation laboratory activations. These metrics are not merely operational efficiencies; they represent a fundamental improvement in patient survival rates and a reduction in the economic burden of unnecessary procedures.

The financial trajectory of Powerful Medical further illustrates the maturity of their leadership. In 2024, they secured a €2.5 million grant and a €5 million follow-on investment from the European Innovation Council (EIC), followed by a massive €40 million IPCEI grant. This capital injection is being utilised to fund multi-centre randomised controlled trials (RCTs) across three countries, providing the high-level clinical validation required for a planned entry into the United States market. The Hermans have demonstrated that Slovakian MedTech can compete for the most prestigious and competitive innovation funding in the European Union, positioning Bratislava as a primary node in global AI cardiology.

2) Dr. Roman Bohac: Digitising the Acute Care Pathway

While Powerful Medical focuses on diagnostic interpretation, Dr. Roman Bohac, the founder of STEMIglobal, has focused on the operational and communicative gaps in emergency medicine. Founded in 2017, STEMIglobal addresses the critical "golden hour" in cardiovascular and stroke care. Bohac’s leadership has been characterised by a focus on "democratising" access to specialists. The STEMI platform enables paramedics in rural or pre-hospital settings to share real-time ECG data and clinical information with specialised cardiology or stroke centres.

This intervention addresses a systemic causal relationship between geographical location and clinical outcomes. By ensuring that a specialist can review a patient’s status before they arrive at the hospital, Bohac has effectively shifted the triage process from the emergency room to the ambulance. This digitisation of the acute care pathway is a necessary precursor to the widespread adoption of AI tools like PMcardio, as it builds the tele-medical infrastructure required for real-time data exchange.

3) Allan Böhm and Nikola Jajcay: The Personalisation of Preventive Cardiology

The work of Allan Böhm and Nikola Jajcay at Seerlinq represents the third pillar of the Slovakian cardiovascular cluster: long-term, personalised monitoring. While the Hermans and Bohac focus on acute events, Seerlinq utilises machine learning to analyse photoplethysmogram (PPG) signals, the pulse data captured by ubiquitous wearable devices, to personalise the treatment and diagnostics of cardiovascular diseases.

The strategic implication of Seerlinq’s work is the transition of cardiology from a reactive to a proactive specialty. By identifying subtle changes in PPG signals that may precede a clinical event, Böhm and Jajcay are providing tools that allow for medication adjustments and lifestyle interventions in a home-care setting. This aligns with broader European health trends toward "bringing care home," a priority identified by EIT Health as occupying $46\%$ of recent innovation submissions.

Leader(s)	Organisation	Primary Technology	Market Focus	Funding / Recognition
Martin & Robert Herman	Powerful Medical	AI-ECG Analysis	Global (EU/US)	€47.5M+ (EIC/IPCEI)
Dr. Roman Bohac	STEMIglobal	Tele-Medical Triage	CEE / Middle East	EIT Health RIS Participant
Allan Böhm & Nikola Jajcay	Seerlinq	ML PPG Analysis	Personalized Care	Seed Stage

Pioneers in Molecular Diagnostics and Precision Oncology

The Slovakian scientific community has long excelled in chemistry and molecular biology, a heritage that is now being commercialised through a new generation of leaders focusing on non-invasive cancer diagnostics. These individuals are moving beyond the traditional reliance on tissue biopsies toward a "liquid biopsy" paradigm that utilises advanced proteomics and glycomics.

4) Pavol Cekan: The Global-Local Catalyst for Precision Oncology

Dr. Pavol Cekan, the founder and CEO of MultiplexDX, is perhaps the most influential bridge between the global scientific community and the Slovakian innovation ecosystem. With over 15 years of experience at institutions such as Rockefeller University and the National Cancer Institute, Cekan brought world-class expertise in nucleic acid chemistry back to Bratislava. His work is centred on eliminating cancer misdiagnosis through a dual-technology approach that combines RNA fluorescence in situ hybridisation (RNA FISH) and RNA sequencing (RNAseq).

This cross-validation method provides oncologists with a 98% accurate, quantitative profile of a patient's cancer markers, enabling the prescription of highly personalized treatment regimens. Beyond his work in oncology, Cekan’s leadership during the COVID-19 pandemic demonstrated the strategic importance of domestic diagnostic capabilities. MultiplexDX developed nine different RT-PCR and LAMP tests, which were registered and distributed in 26 countries. His public service, recognised by the Order of Ľudovít Štúr II. class, has elevated the profile of Slovakian science to a level of national priority.

5) Jan Tkac and Tomas Bertok: Deciphering the Glycocode

Drs. Jan Tkac and Tomas Bertok, the founders of Glycanostics, represent the pinnacle of academic-to-commercial translation in Slovakia. Both recipients of the "Scientist of the Year" award, they established Glycanostics in 2017 to bring their research on glycobiology to the diagnostic market. Their work focuses on glycan changes, complex carbohydrate structures, attached to specific proteins such as the Prostate-Specific Antigen (PSA).

The significance of their technology lies in its ability to overcome the limitations of the current PSA screening paradigm, which frequently results in unnecessary biopsies due to low specificity. The Glycanostics GIA (Glycobiopsy ImmunoAssay) test utilises a unique magnetic bead-based protocol to enrich proteins from human serum and perform glycoprofiling. In clinical validation studies, their "prostate glycan index" (PGI) outperformed the standard Prostate Health Index (PHI), achieving an Area Under the Curve (AUC) of 0.821 for discriminating between the presence and absence of cancer, and 0.90 for therapy monitoring. By providing a more precise "second opinion" test, Tkac and Bertok are directly reducing the physical and psychological burden of cancer screening on the male population.

6) Lukáš Alner: Democratising Specialist Access

While Cekan and Tkac focus on the biological detection of disease, Lukáš Alner, the founder of Diagnose.me, has focused on the informational democratisation of the diagnostic process. Diagnose.me operates a global platform that connects patients with world-leading medical specialists for second opinions.

In a region where access to highly specialised medical expertise may be geographically concentrated, Alner’s platform provides a vital layer of diagnostic assurance. This service is particularly relevant in complex oncological cases where a second opinion can alter the entire course of treatment, preventing medical errors and improving long-term outcomes.

Leader	Organization	Core Innovation	Diagnostic Metric	Funding / Stage
Pavol Cekan	MultiplexDX	RNA FISH + RNAseq	98% Accuracy	Seed A (€1.2M)
Jan Tkac / Tomas Bertok	Glycanostics	Glyco-profiling	AUC 0.82-0.90	EIC Accelerator / ERC
Lukáš Alner	Diagnose.me	Tele-Specialist Network	N/A	Seed / Series Unknown

The Platform Revolution: Synthetic Biology and Genomic Intelligence

As healthcare moves toward the molecular level, Slovakian leaders are developing foundational platforms for the next generation of therapeutics and personalised wellness. This involves the integration of high-performance computing with biological manufacturing.

7) Miroslav Gasparek: Pioneering Cell-Based mRNA Manufacturing

Miroslav Gasparek, the CEO and co-founder of Sensible Biotechnologies, is addressing one of the most critical bottlenecks in contemporary pharmacology: the manufacturing of mRNA. Traditional mRNA production relies on In Vitro Transcription (IVT), a cell-free method that often fails to meet the quality and purity requirements for chronic therapeutic applications. Gasparek’s leadership is defined by the development of a cell-based platform that utilises precision fermentation and computational biology to produce non-immunogenic, highly functional mRNA inside living cells.

A major milestone in Gasparek's strategic vision was the integration of NVIDIA's accelerated computing and AI into their molecular design process. By utilising NVIDIA DGX Cloud and H100 GPUs, Sensible Biotechnologies has reduced its mRNA optimisation cycles by over 90%, cutting the time required from 15 days to just 24 hours. With over $13 million in funding from elite investors such as Y Combinator and BlueYard Capital, Gasparek is positioning Sensible Biotechnologies not just as a biotech firm, but as a critical infrastructure provider for the future of programmable medicine.

8) Michaela Šišková and Jakub Šiška: Genomic Literacy and Preventive Health

In the consumer-facing segment of genomics, Michaela Šišková and Jakub Šiška have established DNA ERA as the leading provider of personalized genetic testing in the region. Their work involves the analysis of metabolic, athletic, and nutritional predispositions through non-invasive DNA tests.

The underlying trend reflected in DNA ERA’s success is the shift toward "proactive health management" among the general population. By translating complex genetic data into actionable insights, the Šiškás are fostering a cultural shift toward preventive lifestyle interventions, which is essential for mitigating the long-term impact of non-communicable diseases on the public healthcare system.

9) Filip Nemcko: The Next Generation of Gene Function Research

Representing the high-potential academic pipeline is Filip Nemcko, a Research Associate at the Research Institute of Molecular Pathology (IMP) and a member of the Forbes Slovakia "30 Under 30" class of 2024. Nemcko was recognised for his role in developing methods that significantly accelerate the understanding of human gene functions.

His early achievements, including a second-place finish in the iGEM synthetic biology competition for a yeast-based cancer detection prototype, signal a future leader capable of bridging advanced research with clinical application. Nemcko’s work holds the potential to unlock new therapeutic targets for genetic diseases, providing the basic science that will power the MedTech startups of the 2030s.

Operational Excellence and Healthcare Infrastructure

The efficiency of a healthcare system is often determined by its administrative and logistical "plumbing." Several Slovakian leaders have identified and solved these systemic inefficiencies, creating scalable solutions for clinical management and trial logistics.

10) Peter Zajac: Digitising Compliance in the Surgery Center

Peter Zajac, co-founder of Surglogs, has tackled the pervasive issue of administrative burden in surgical environments.Surglogs provides a digital platform that automates the management of regulatory compliance logbooks, medication supplies, and safety drills. By replacing antiquated paper systems, Zajac’s team is not only improving operational efficiency but also enhancing patient safety.

In a high-stakes surgical environment, the ability to instantaneously verify compliance and supply levels reduces the risk of medical errors. Surglogs’ successful Series A funding and its expansion into the US market demonstrate that Slovakian entrepreneurs can solve universal operational challenges in global healthcare systems.

11) Martin Winkler: The Logistical Backbone of Clinical Trials

The complexity of clinical trials is a major barrier to drug development. Martin Winkler, the founder of Meliovit, addresses this through a specialised logistics platform for clinical trials. Meliovit focuses on the secure, direct-to-patient delivery of materials and the efficient handling of clinical data.

As clinical trials become increasingly decentralised and personalised, Winkler’s leadership in logistical optimisation ensures that the underlying data remains robust and that patients in remote locations can participate in groundbreaking research. This is a critical enabler for the biotech startups like Sensible Biotechnologies that require high-velocity trial cycles to validate their platforms.

12) Miroslav Kočan: Optimising the Ambulatory Workflow

Miroslav Kočan, alongside founders Martin Minka and Daniel Dzurov, developed CURO to solve the administrative bottlenecks faced by primary and ambulatory care physicians. The CURO system streamlines the process of insurance performance checks and clinical documentation.

While less prominent than AI-driven surgery, these innovations are vital for preserving the human resources of the healthcare system. By reducing the time doctors spend on paperwork, Kočan and his team are effectively increasing the clinical capacity of the ambulatory sector, a crucial intervention in the face of widespread medical staff shortages.

13) Patrik Kmeč and Roman Kučera: The Hilbi Health Ecosystem

One of the most significant recent financial milestones in the Slovakian HealthTech sector was the €8 million strategic investment secured by Hilbi, led by founders Patrik Kmeč and Roman Kučera. Hilbi is a patient-centric platform that unifies electronic health records (EHR), transactional management, and AI-driven analytics into a borderless ecosystem.

The innovation of Kmeč and Kučera lies in their decentralized architecture, which treats patients as "clients" who have ownership over their health data. The impact of this approach is measurable; clinics using Hilbi have reported a 20% increase in workflow efficiency and a revenue boost of up to 35%. By facilitating the monetisation of anonymous health data via blockchain, Hilbi is creating a new economic model for healthcare that incentivises data sharing for the benefit of global research. Their recent expansion into the Indian market highlights the global scalability of Slovakian health data platforms.

Leader	Organization	Focus Area	Funding / Impact
Peter Zajac	Surglogs	Surgical Compliance	Series A / US Market
Martin Winkler	Meliovit	Trial Logistics	Seed / Data Integrity
Miroslav Kočan	CURO	Ambulatory Efficiency	N/A / Workflow Optimization
Patrik Kmeč / Roman Kučera	Hilbi	Health Data/Blockchain	€8M Investment / 100k+ users

Wellness, Nutrition and the Digitalisation of Mental Health

The boundary between medical treatment and proactive wellness is blurring, and Slovakian leaders are at the forefront of this "preventive revolution," utilising digital tools to address nutrition and mental health at scale.

14) Michal Palenik: Scientific Nutrition at Scale

Michal Palenik, the founder of Planeat, has transformed nutritional science into a scalable digital application. Recognising that nutrition is a fundamental determinant of health outcomes in chronic conditions such as diabetes and cardiovascular disease, Palenik developed a platform that creates personalised meal plans based on individual clinical profiles and dietary goals.

Planeat’s integration into the medical workflow allows healthcare professionals to prescribe nutritional interventions with the same precision as pharmaceuticals, bridging the gap between clinical advice and daily behavioural execution.

The Mentegram Team: Digitising Behavioral Health

Mental health has long been underserved by traditional MedTech, but the team behind Mentegram is changing this through AI-driven assessment tools. Mentegram provides a platform for clinicians to conduct mental health assessments and monitor patient progress in real-time.

By utilising AI to suggest personalised treatment plans for conditions like depression and substance abuse, Mentegram is effectively increasing the "reach" of a limited number of mental health specialists. Their work is critical for destigmatising mental healthcare and making it a standard component of integrated medical care.

Institutional Research and Academic Excellence

The long-term viability of the Slovakian MedTech sector is anchored by its academic institutions, where researchers are developing the biological and engineering frameworks for future innovations.

15) Andrea Lauková: A Leader in Postbiotic Science

Dr. Andrea Lauková of the Centre of Biosciences at the Slovak Academy of Sciences (SAS) was awarded the SISA Scientist of the Year 2025 for her pioneering work in microbiology and biological sciences. Her research focuses on the antimicrobial activity of proteinaceous postbiotic substances and bacteriocins, such as Enterocin M.

The implications of Lauková’s work are profound for both human and animal health. As the global threat of antibiotic resistance grows, her discovery of autochthonous strains like Enterococcus faecium EF 412—which shows significant activity against methicillin-resistant Staphylococcus aureus (MRSA), provides a viable alternative to traditional antibiotics.

Her research into the fortification of dairy products with encapsulated postbiotic active lactococci further demonstrates the commercial potential of her work in the functional food and nutraceutical sectors.

16) Peter Celec: Advancing Molecular Biomedicine

Professor Peter Celec, head of the Institute of Molecular Biomedicine at Comenius University, is a central figure in Slovakian medical research. His work is characterised by a high degree of inter-disciplinarity, involving molecular biology, biophysics and clinical medicine.

Celec’s current research on the biology of extracellular DNA and the role of neutrophil extracellular traps in gastrointestinal autoimmunity is at the cutting edge of biomedical science. His leadership in training a new generation of PhD students in experimental and laboratory medicine ensures that the "talent pipeline" for the Slovakian HealthTech sector remains robust.

17) Juraj Beniak: Innovation in Additive Manufacturing for Medicine

At the Slovak University of Technology (STU), Professor Juraj Beniak has emerged as a leader in the field of additive manufacturing, receiving the Technologist of the Year 2024 award. His work in developing innovative composite materials and design solutions for 3D printing has direct applications in MedTech, particularly in the creation of customized implants and medical equipment.

During the COVID-19 pandemic, Beniak’s research was instrumental in the rapid production of respirators using antibacterial nano-composite materials. His work illustrates the strategic importance of technical universities in providing the "hard engineering" capabilities required for medical device manufacturing.

18) 19) Aleksander Kasprzak and Martin Michalko: Building the Trial Ecosystem

Aleksander Kasprzak and Martin Michalko, the founders of Biogenesis Trials, are creating a new clinical trial ecosystem in Slovakia. Their mission is to accelerate drug development by fostering deeper collaboration between researchers and clinicians.

In a region that is often a preferred location for clinical trials due to its high-quality medical infrastructure, Biogenesis Trials is providing the connective tissue that allows domestic research to reach global standards. This is a critical factor for the retention of medical talent, as it provides clinicians with opportunities to engage in high-level international research without leaving Slovakia.

20) Vlado Beňo: Revolutionising Sensor Technology

Vlado Beňo, alongside Michal and Rastislav Beňo, founded RVmagnetics to push the boundaries of sensor technology.Their miniaturised magnetic sensors have diverse applications in healthcare, ranging from smart orthopedic implants to real-time physiological monitoring.

By integrating sensors directly into medical devices, RVmagnetics enables the "Internet of Medical Things" (IoMT), where devices can provide continuous feedback to clinicians. This is a foundational technology for the next generation of smart prosthetics and remote monitoring tools.

Academic Leader	Institution	Recognition	Research Specialty
Andrea Lauková	SAS	Scientist of the Year 2025	Postbiotics / Antimicrobials
Juraj Beniak	STU	Technologist of the Year 2024	Additive Manufacturing
Peter Celec	Comenius Univ.	VEGA Grantee	Molecular Biomedicine
Roman Gardlík	Comenius Univ.	Dept. Head (IMBM)	Molecular Biology

The Role of Ecosystem Enablers and Strategic Funding

The success of these 20 leaders is not an isolated achievement but the result of a supportive ecosystem that includes international accelerators, regional venture capital, and European innovation programs.

The EIT Health InnoStars and RIS Innovation Calls have been pivotal in providing early-stage support for Slovakian innovators. Programs like the EIT Health Catapult, which provides 360° training and exposure to over 450 investors, have served as a "launchpad" for companies like Powerful Medical and Sensible Biotechnologies.

Furthermore, the emergence of domestic funds like ZAKA VC, which recently unveiled a €15 million fund to support early-stage startups across Europe and the US, provides the necessary local capital for initial scaling.

The strategic importance of Slovakia’s technical education is also evident in the ranking of the Slovak University of Technology (STU) as the best technical university in Slovakia by EngiRank 2024. STU’s participation in the EULiST alliance of European universities facilitates the international mobility of researchers and students, ensuring that the local talent pool remains competitive with global benchmarks.

Strategic Synthesis and Future Trajectory

The collective work of these 20 leaders indicates that Slovakia is carving out a distinct niche in the global HealthTech market. This niche is characterised by:

AI-Driven Cardiovascular Diagnostics: A dominant cluster led by Powerful Medical that is setting new European standards for acute care coordination.
Advanced Molecular Screening: A focus on non-invasive diagnostics using glycomics and RNA sequencing to eliminate clinical errors in oncology.
Biological Platform Technologies: The development of cell-based manufacturing systems for mRNA, addressing the foundational supply chain challenges of modern medicine.
Decentralised Health Data: A shift toward blockchain-backed, patient-centric data ecosystems that facilitate global research collaboration.

The transition of Slovakian MedTech from a domestic curiosity to a global competitor is nearly complete.

The next phase, beginning in 2025, will be defined by the successful penetration of these technologies into the North American and Asian markets, and the continued integration of domestic academic research into commercial pipelines.

The leaders identified in this report are not just the "future" of Slovakian healthcare; they are the present force driving the modernisation of medicine across the European continent. Their success serves as a blueprint for how a small, technically proficient nation can leverage its academic heritage to solve the most pressing challenges in global health.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech